Core Viewpoint - Guangkang Biotech (300804.SZ) received a warning letter from the Guangdong Securities Regulatory Bureau regarding the improper management of raised funds, specifically concerning the purchase of non-principal guaranteed financial products without adequate disclosure of associated risks [1] Group 1: Regulatory Actions - The company was issued a warning letter (Decision No. 〔2025〕179) by the Guangdong Securities Regulatory Bureau [1] - The investigation covered the period from July 2023 to August 2025, during which the company engaged in cash management using raised funds [1] Group 2: Fund Management Practices - The company executed 179 transactions to purchase financial products, of which 158 were non-principal guaranteed products [1] - The breakdown of non-principal guaranteed product purchases includes 14 in 2023, 68 in 2024, and 76 in 2025 [1] - The company failed to adequately disclose the risks of potential principal loss in its annual reports regarding the use of raised funds [1] Group 3: Compliance Violations - The company's actions were found to be non-compliant with the regulatory requirements outlined in the "Guidelines for the Supervision of Listed Companies on the Management and Use of Raised Funds" [1] - Violations included not fully disclosing the safety of principal when using raised funds for cash management [1]
广康生化(300804.SZ)及相关人员收到广东证监局警示函